Skip to content
All articles

Phase 2 trial of organ-preserving multimodal therapy for patients with high-risk upper tract urothelial carcinoma

Prof. Wei Xue
Prof. Wei Xue

Radical nephroureterectomy is the standard treatment for patients with high-risk upper tract urothelial carcinoma (UTUC), but causes irreversible nephron loss and can limit subsequent systemic therapy. The phase 2 DISTINCT-I trial at two centers in China (Renji Hospital of Shanghai Jiao Tong University and the Second Hospital of Tianjin Medical University) evaluated a response-adapted kidney-preserving strategy integrating induction disitamab vedotin plus tislelizumab for two to four cycles, selective kidney-sparing surgery when feasible, and longitudinal ctDNA and urinary tumor DNA monitoring in patients with localized high-risk UTUC and ECOG performance status 0-2. The primary endpoint was 1-year kidney-intact event-free survival rate. A total of 36 patients were assessed for eligiblity, ten did not meet the eligibility criteria, and six declined to participate. Of the 20 patients enrolled, 17 (85%) were male and three (15%) were female. At data cutoff, median follow-up was 17.0 months (IQR 14.0-23.0). The 1-year kidney-intact event-free survival rate was 70% (95% CI 46-88). Grade 3 treament-related adverse events occurred in two patients (10%), no grade 4 or 5 TRAEs, serious TRAEs, or treatment-related deaths occurred. The authors conclude that this multimodal treatment strategy was associated with kidney preservation in selected patients with high-risk UTUC. These findings support further prospective comparative evaluation of organ-preserving strategies in patients with high-risk UTUC.

Original publicationthelancet.com
Read the publication